Spots Global Cancer Trial Database for insulinoma
Every month we try and update this database with for insulinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | NCT04185350 | Insulinoma | 68Ga-NOTA-MAL-C... | 18 Years - 75 Years | Nanjing First Hospital, Nanjing Medical University | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | NCT02021604 | Congenital Hype... Insulinoma | Fluorodopa F 18 | - 18 Years | Cook Children's Health Care System | |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | NCT00602082 | Gastrointestina... Islet Cell Tumo... | capecitabine cisplatin streptozocin DNA analysis RNA analysis protein analysi... proteomic profi... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | NCT01056601 | Pancreatic Canc... | Bortezomib Panobinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| EUS-guided Ethanol Ablation of an Insulinoma | NCT02121366 | Insulinoma | EUS-guided etha... | 18 Years - 80 Years | Guangxi Medical University | |
| Pasireotide in Hyperinsulinemic Hypoglycemia | NCT03053284 | Congenital Hype... Insulinoma Hyperinsulinism | Pasireotide 0.6... Saline Solution | 18 Years - 70 Years | Montefiore Medical Center | |
| The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | NCT04979611 | Insulinoma | 68Ga-NOTA-exend... | 6 Years - 70 Years | First Affiliated Hospital of Fujian Medical University | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | NCT05034783 | Insulinoma | [68Ga]Ga-HBED-C... [68Ga]Ga-NOTA-e... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | NCT00416767 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | Federation Francophone de Cancerologie Digestive | |
| CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | NCT04452396 | Hypoglycemia, R... Hypoglycaemia N... Hypoglycemia No... Hypoglycemia Un... Insulinoma Insulinoma; Mal... Insulin Hypogly... Insulin Resista... Spontaneous Hyp... Neuro Endocrine... | use of continuo... | 18 Years - 90 Years | Barts & The London NHS Trust | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism | NCT00325104 | Hypercalcemia Familial Primar... | Parathyroid hor... Serum calcium t... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | NCT00227617 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... Neuroendocrine ... | bevacizumab 5-fluorouracil leucovorin oxaliplatin | 18 Years - | University of California, San Francisco | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00027638 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... | thalidomide | - | Memorial Sloan Kettering Cancer Center | |
| Application of Raw Corn Starch on Patients With Insulinoma | NCT03930368 | Hyperinsulinemi... Insulinoma Raw Corn Starch | low GI diet wit... | 18 Years - | Peking Union Medical College Hospital | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | NCT02259725 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Somatostatinoma | regorafenib laboratory biom... | 18 Years - | University of Southern California | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism | NCT00325104 | Hypercalcemia Familial Primar... | Parathyroid hor... Serum calcium t... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00027638 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... | thalidomide | - | Memorial Sloan Kettering Cancer Center | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | NCT02273752 | Estrogen Recept... Gastrinoma Glucagonoma HER2-negative B... Insulinoma Mucositis Oral Complicati... Pancreatic Poly... Progesterone Re... Recurrent Breas... Recurrent Islet... Recurrent Renal... Somatostatinoma Stage III Renal... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Renal ... | Everolimus | 18 Years - | Emory University | |
| Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | NCT04185350 | Insulinoma | 68Ga-NOTA-MAL-C... | 18 Years - 75 Years | Nanjing First Hospital, Nanjing Medical University | |
| 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia | NCT01916148 | Congenital Hype... Beckwith-Wiedem... Insulinoma | 18F-DOPA | - | Children's Hospital of Philadelphia | |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00017199 | Gastrointestina... Islet Cell Tumo... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients | NCT00937079 | Hyperinsulinism Hypoglycemia Insulinoma | 111In-exendin-4... | 18 Years - 90 Years | University Hospital, Basel, Switzerland | |
| Blinded Resection in Case of the Pancreatic Insulinoma | NCT04741152 | Insulinoma; Pan... | Pancreatic rese... | - | Vishnevsky Center of Surgery | |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | NCT00466856 | Head and Neck C... Islet Cell Tumo... Metastatic Canc... Pheochromocytom... | octreotide acet... yttrium Y 90 re... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | NCT02021604 | Congenital Hype... Insulinoma | Fluorodopa F 18 | - 18 Years | Cook Children's Health Care System | |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | NCT02108782 | Gastrinoma Glucagonoma Insulinoma Pancreatic Poly... Recurrent Islet... Somatostatinoma | dovitinib lacta... pharmacological... laboratory biom... | 18 Years - | Academic and Community Cancer Research United | |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00131911 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Neuroendocrine ... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | sorafenib tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| 18F-FDOPA PET in Neuroendocrine Tumours | NCT02431715 | Thyroid Cancer,... Carcinoid Tumor Pheochromocytom... Paraganglioma Insulinoma Neuroblastoma | [18 F]-6-L-fluo... | 1 Month - | British Columbia Cancer Agency | |
| CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | NCT04452396 | Hypoglycemia, R... Hypoglycaemia N... Hypoglycemia No... Hypoglycemia Un... Insulinoma Insulinoma; Mal... Insulin Hypogly... Insulin Resista... Spontaneous Hyp... Neuro Endocrine... | use of continuo... | 18 Years - 90 Years | Barts & The London NHS Trust | |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | NCT00416767 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | Federation Francophone de Cancerologie Digestive | |
| A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct | NCT05523778 | Insulinoma | placement of pa... Direct enucleat... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | NCT02021604 | Congenital Hype... Insulinoma | Fluorodopa F 18 | - 18 Years | Cook Children's Health Care System | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00017199 | Gastrointestina... Islet Cell Tumo... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | NCT02259725 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Somatostatinoma | regorafenib laboratory biom... | 18 Years - | University of Southern California | |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | NCT00006368 | Brain and Centr... Breast Cancer Gastrointestina... Islet Cell Tumo... Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Synd... | yttrium Y 90-ed... | 18 Years - | Novartis | |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT00084461 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Regional Gastro... Somatostatinoma | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | NCT02031536 | Gastrinoma Glucagonoma Insulinoma Liver Metastase... Pancreatic Poly... Recurrent Islet... Somatostatinoma | everolimus placebo | 18 Years - | Eastern Cooperative Oncology Group | |
| Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients | NCT00937079 | Hyperinsulinism Hypoglycemia Insulinoma | 111In-exendin-4... | 18 Years - 90 Years | University Hospital, Basel, Switzerland | |
| Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | NCT02021604 | Congenital Hype... Insulinoma | Fluorodopa F 18 | - 18 Years | Cook Children's Health Care System | |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer | NCT00096083 | Cancer | isolated perfus... melphalan | 16 Years - | Delcath Systems Inc. | |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT00084461 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Regional Gastro... Somatostatinoma | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | NCT01525082 | Gastrinoma Glucagonoma Insulinoma Pancreatic Poly... Recurrent Islet... Recurrent Pancr... Somatostatinoma Stage III Pancr... Stage IV Pancre... | Capecitabine Temozolomide Bevacizumab | 18 Years - | Stanford University | |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01824875 | Gastrinoma Glucagonoma Insulinoma Islet Cell Carc... Pancreatic Poly... Recurrent Islet... Somatostatinoma | temozolomide capecitabine | 18 Years - | Eastern Cooperative Oncology Group | |
| Diagnosing and Treating Low Blood Sugar Levels | NCT00001276 | Hypoglycemia Insulinoma | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
